Cargando…
Systemic adjuvant therapy for high-risk cutaneous melanoma
Cutaneous melanoma continues to increase in incidence and poses a significant mortality risk. Surgical excision of melanoma in its early stages is often curative. However, patients with resected stages IIB-IV are considered at high risk for relapse and death from melanoma where systemic adjuvant the...
Autores principales: | Kobeissi, Iyad, Tarhini, Ahmad A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619267/ https://www.ncbi.nlm.nih.gov/pubmed/36324735 http://dx.doi.org/10.1177/17588359221134087 |
Ejemplares similares
-
Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field
por: Eljilany, Islam, et al.
Publicado: (2023) -
Adjuvant Therapy: Melanoma
por: Davar, Diwakar, et al.
Publicado: (2011) -
A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab
por: Kobeissi, Iyad, et al.
Publicado: (2023) -
Adjuvant therapy for high-risk melanoma
por: Eggermont, Alexander M.M.
Publicado: (2013) -
An update on adjuvant systemic therapies in melanoma
por: Samuel, Evangeline, et al.
Publicado: (2019)